Diabetes Care 43(11):28822885
Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases
" 100k+ Patients Agree - When nothing else worked, FeelGood did " - brand-reported patient count and brand-curated testimonial framing
Given the current evidence gaps, incretin-based medications should not be considered established lipedema treatments
More common with compounded formulations than with brand-name pens, possibly due to differences in solution pH, concentration, or inactive ingredients
6X1A: Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, Underwood CR, Egebjerg T, enel P, Stewart GD, Liang YL, Glukhova A, Venugopal H, Christopoulos A, Furness SGB, Miller LJ, Reedtz-Runge S, Langmead CJ, Gloriam DE, Danev R, Sexton PM, Wootten D